[go: up one dir, main page]

NO20091234L - Polymorfine krystallformer av et indan-2-ylamino-hydroksyetyl-kinolinonmaleatderivat som beta-adrenoceptoragonist - Google Patents

Polymorfine krystallformer av et indan-2-ylamino-hydroksyetyl-kinolinonmaleatderivat som beta-adrenoceptoragonist

Info

Publication number
NO20091234L
NO20091234L NO20091234A NO20091234A NO20091234L NO 20091234 L NO20091234 L NO 20091234L NO 20091234 A NO20091234 A NO 20091234A NO 20091234 A NO20091234 A NO 20091234A NO 20091234 L NO20091234 L NO 20091234L
Authority
NO
Norway
Prior art keywords
indan
ylamino
hydroxyethyl
polymorphine
quinolinone
Prior art date
Application number
NO20091234A
Other languages
English (en)
Norwegian (no)
Inventor
Olivier Lohse
Guido Jordine
Stephanie Monnier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091234(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20091234L publication Critical patent/NO20091234L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20091234A 2006-08-31 2009-03-24 Polymorfine krystallformer av et indan-2-ylamino-hydroksyetyl-kinolinonmaleatderivat som beta-adrenoceptoragonist NO20091234L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119895A EP1914227A1 (en) 2006-08-31 2006-08-31 Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
PCT/EP2007/059039 WO2008025816A1 (en) 2006-08-31 2007-08-30 Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist

Publications (1)

Publication Number Publication Date
NO20091234L true NO20091234L (no) 2009-03-30

Family

ID=37714644

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091234A NO20091234L (no) 2006-08-31 2009-03-24 Polymorfine krystallformer av et indan-2-ylamino-hydroksyetyl-kinolinonmaleatderivat som beta-adrenoceptoragonist

Country Status (21)

Country Link
US (1) US20100010039A1 (ru)
EP (2) EP1914227A1 (ru)
JP (1) JP2010501631A (ru)
KR (1) KR20090049615A (ru)
CN (1) CN101511794A (ru)
AR (1) AR063698A1 (ru)
AU (1) AU2007291270A1 (ru)
BR (1) BRPI0716383A2 (ru)
CA (1) CA2659144A1 (ru)
CL (1) CL2007002525A1 (ru)
GT (1) GT200900037A (ru)
IL (1) IL196805A0 (ru)
MA (1) MA30763B1 (ru)
MX (1) MX2009002301A (ru)
NO (1) NO20091234L (ru)
PE (1) PE20080923A1 (ru)
RU (1) RU2009111389A (ru)
TN (1) TN2009000056A1 (ru)
TW (1) TW200817333A (ru)
WO (1) WO2008025816A1 (ru)
ZA (1) ZA200900264B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481738A1 (en) * 2009-09-25 2012-08-01 Kyorin Pharmaceutical Co., Ltd. Maleic acid salt and crystal thereof
ES2626829T3 (es) 2013-03-27 2017-07-26 Laboratorios Lesvi, S.L. Procedimiento para la fabricación de (R)-5[2-(5,6-dietil-indan-2-ilamino)-1-hidroxietil]-8-hidroxi-(1H)-quinolin-2-ona
CN103830195A (zh) * 2014-03-11 2014-06-04 熊妲妮 一种茚达特罗片及其制备方法
CN103830193A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗片制剂及其制备方法
EP3347345B1 (en) 2015-09-29 2019-07-31 Inke, S.A. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one l-tartrate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1914227A1 (en) 2008-04-23
RU2009111389A (ru) 2010-10-10
KR20090049615A (ko) 2009-05-18
MA30763B1 (fr) 2009-10-01
IL196805A0 (en) 2009-11-18
TN2009000056A1 (en) 2010-08-19
ZA200900264B (en) 2010-05-26
CN101511794A (zh) 2009-08-19
CL2007002525A1 (es) 2008-07-11
TW200817333A (en) 2008-04-16
BRPI0716383A2 (pt) 2013-09-24
CA2659144A1 (en) 2008-03-06
AU2007291270A1 (en) 2008-03-06
JP2010501631A (ja) 2010-01-21
GT200900037A (es) 2010-03-11
WO2008025816A1 (en) 2008-03-06
PE20080923A1 (es) 2008-07-11
US20100010039A1 (en) 2010-01-14
MX2009002301A (es) 2009-03-20
EP2066639A1 (en) 2009-06-10
AR063698A1 (es) 2009-02-11

Similar Documents

Publication Publication Date Title
WO2010151710A3 (en) Substituted heterocyclic compounds as kinases inhibitors and method of use thereof
NO20070893L (no) Hydantoinderivater for behandling av inflammasjonslidelser.
WO2008116920A3 (de) 17beta-hydroxysteroid-dehydrogenase-typ1-inhibitoren zur behandlung hormonabhängiger erkrankungen
NO20091234L (no) Polymorfine krystallformer av et indan-2-ylamino-hydroksyetyl-kinolinonmaleatderivat som beta-adrenoceptoragonist
WO2011026911A8 (en) Bipyridines useful for the treatment of proliferative diseases
NO20054452D0 (no) Fremgangsmate for fremstilling av 5-[(R)-2-(5,6-dietyl-indan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolin-2-on-salt som er nyttig som adrenoreseptoragonist
WO2008011109A3 (en) Substituted pyridone compounds and methods of use
NO20056130L (no) Nye substituerte 3-svovelindoler
DK1539700T3 (da) 8-hydroxyquinolin-derivater
WO2007125547A3 (en) Novel process for statins and its pharmaceutically acceptable salts thereof
WO2010007046A3 (en) Heteroaryl derivatives as dgat1 inhibitors
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
WO2006110816A3 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2009024823A8 (en) Cyclopropyl amide derivatives
WO2008059223A3 (en) Process for the synthesis of moxifloxacin hydrochloride
WO2008058118A3 (en) Preparation of montelukast and its salts
NO20092634L (no) Fremgangsmate for fremstilling av piperazinyl og diazepanyl benzamidderivater
IN2012DN01273A (ru)
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
WO2008012338A3 (en) Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
NO20080033L (no) Kinolinderivater som NK3-antagonister
WO2007121389A3 (en) 4,4-disubstituted piperidine derivatives as nk-i and serotonin transporter inhibitors
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
EA200900985A1 (ru) Способ получения оптически чистого омепразола
WO2008049922A3 (en) A new process for the preparation of montelukast

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application